ASND — Q2 2026 Financial Report Analysis

Overview

Ascendis Pharma, the Copenhagen-based maker of long-acting hormone therapies, more than doubled its sales in the second quarter of 2026. Total revenue was €339.3 million, against €158.0 million a year earlier (+115%). Product sales were €314.9 million (+105%), and almost all of the increase came from YORVIPATH, its treatment for hypoparathyroidism (a rare condition in which the body makes too little parathyroid hormone to control calcium levels). YORVIPATH sold €252.1 million, up from €103.0 million, which the company attributes to "consistent new patient demand in the U.S." The headline profit is far larger than the underlying business: a reported net profit of €207.0 million (€2.83 per diluted share) includes a one-off €158.1 million gain from selling a regulatory voucher. Under the company's adjusted (non-IFRS) measure, which strips that out, net profit was €61.3 million, or €0.90 per share.

At a glance

• YORVIPATH: €252.1M, +145% year on year and +28% on Q1. It now makes up 80% of product sales, so the company's growth depends mostly on this one drug.
• Operating profit without the voucher sale: about €62M, an 18% margin. Ascendis is profitable from selling drugs alone. A year ago it lost €53M at the operating line.
• Cash: €812M at June 30, up from €616M at year-end. That is after €103M of share buybacks in the first half, and the convertible notes have been turned into shares.

The numbers

"n/m" = not meaningful: a percentage change from a loss to a profit has no useful interpretation. All figures are from the company's IFRS statements (IFRS is the international accounting standard Ascendis reports under) and its non-IFRS reconciliation.

Product by product

YORVIPATH (hypoparathyroidism). The company calls it "consistent new patient demand in the U.S." For the first half, YORVIPATH sales were €449.0M, three times the €147.6M from a year earlier. The growth also continued quarter to quarter: Q1 2026 was about €196.9M (first-half sales minus Q2), so Q2 added roughly 28% sequentially. That suggests the launch has not yet flattened out. Outside the US the drug is now available commercially or through named-patient programs (case-by-case supply to individual patients before full approval) in more than 35 countries.

SKYTROFA (growth hormone for children). This is a weekly injection that competes in a crowded market of daily and weekly growth-hormone products. It grew 8.9% year on year to €55.2M and about 26% on a weak Q1 (around €44.0M). First-half SKYTROFA sales were €99.2M against €102.0M in 2025, down 2.8%, so the quarter-on-quarter rebound recovers ground rather than adding new growth. The company cites more than 20,000 unique enrollments globally since launch. A Phase 3 "basket" trial (one study covering several related conditions) is under way and could widen the label to idiopathic short stature, SHOX deficiency, Turner syndrome and children born small for gestational age.

YUVIWEL (achondroplasia, the most common form of dwarfism). In its first partial quarter after FDA approval in February 2026, YUVIWEL sold €7.6M. More useful than the revenue are the early demand figures: through July 31, more than 220 unique US patient enrollments from more than 100 prescribers, with more than 65% of enrollments already approved for reimbursement. The European decision is expected in Q4 2026.

Where the money went

• Cost of sales fell to €27.7M from €31.4M even though revenue more than doubled. Gross margin (the share of revenue left after the direct cost of making the products) therefore rose from 80.1% to 91.8%. The release does not explain the drop. A plausible reading, not one the release states, is that a higher-value product mix and fixed manufacturing costs spread over more units are doing most of the work.
• R&D was €75.9M (+5%). The company says this reflects "increased clinical trial activities within the Endocrinology Rare Disease pipeline, offset by reduced clinical trial activities within Oncology". Ascendis has been moving spending away from cancer programs and toward the rare-endocrine franchise.
• Selling, general and administrative costs were €173.3M (+61%). These are the costs of sales forces, marketing and overhead, and they rose "primarily due to the continued impact from commercial expansion, including global launch activities". They still grew much more slowly than revenue: SG&A fell from 68% of revenue to 51%. That is operating leverage, meaning a fixed cost base spread over faster-growing sales.

What the headline numbers hide

• The €158M voucher sale is a one-off. When the FDA approved YUVIWEL in February, it awarded a Rare Pediatric Disease Priority Review Voucher, a transferable coupon that lets its holder get a future drug reviewed faster. Ascendis sold it in Q2 for €158.1M net, booked as "other operating income". Without it, operating profit was about €62.4M (an 18.4% margin, not 65%). Adjusted operating profit of €92.0M (27.1%) also adds back €29.6M of share-based compensation, which is a real, recurring cost to shareholders through dilution.
• The half-year profit is mostly a tax accounting entry. First-half net profit of €836.3M includes €704.2M from recognising deferred tax assets: past losses that the company now expects to use against future taxable profit, so they are booked as an asset. €24.6M of that fell in Q2. It reflects management's view that profits will last, but it is not cash and will not repeat.
• Cash flow is solid but smaller than the profit. Operating cash flow for the first half was €274.0M, against a €22M outflow a year earlier, and the €158M voucher payment is part of it. Without the voucher, roughly €116M of operating cash came from the business in six months. That is real cash generation and consistent with the adjusted figures, not with the €836M reported profit.
• Receivables are growing fast. Trade receivables (money customers owe but have not yet paid) rose to €206.5M from €141.3M at year-end, up 46% in six months, and absorbed €61M of cash in the half. Sales are also climbing quickly: Q2 total revenue was 38% above Q1's ~€246.6M. So this looks more like growth than a collection problem. It is still the line to watch as US distribution scales up.
• Gross-to-net is not disclosed. US drug makers book revenue after rebates, chargebacks and discounts to insurers and distributors, the gap between list price and the "net" price. The release does not give a gross-to-net figure. Provisions on the balance sheet rose to €221.4M from €166.4M, and for a drug seller they typically include rebate accruals, but the release does not break them down.
• €17.0M of revenue was milestones. Milestone revenue (one-off payments from partners when a development or commercial goal is reached) was zero a year earlier. Without it, total revenue growth would be about 104% rather than 115%.
• The share count went up. Diluted shares rose 6.9% to 68.3M, and the $575M of 2.25% convertible notes (bonds that could be swapped for shares) were all converted into equity in May. That conversion removed €719M of liabilities and turned shareholders' equity from negative €162.8M to positive €1.44bn. €103.4M of buybacks in the first half only partly offset the dilution. About €450M of other borrowings remain.

Takeaway: Without the €158M one-off voucher sale, Ascendis is now an operating profit business, at about €62M and an 18% margin in Q2. That profit rests almost entirely on YORVIPATH, which still grew 28% from Q1 to Q2. The 115% revenue growth rate will fall as year-earlier comparisons get tougher, so the quarter-on-quarter trend for YORVIPATH, plus how quickly YUVIWEL builds, matters more than the year-on-year headline.

Outlook and what to watch

The release gives no financial guidance for revenue or profit. The company sets out these milestones for the rest of 2026:

• YUVIWEL: the European Medicines Agency decision is expected in Q4 2026. The completed enrollment of the pivotal reACHin trial supports planned filings for infants under 2 years old. A Phase 3 trial in hypochondroplasia (a milder, related growth disorder) is expected to start enrolling in the second half.
• Combination therapy: Week 78 data from the COACH trial of TransCon CNP plus TransCon hGH showed all 21 enrolled children still on treatment. A Phase 3 trial in pediatric achondroplasia is expected to start enrolling in Q4 2026.
• YORVIPATH label expansion: the PaTHway60 and PaTHway Adolescent trials are ongoing.

Our read: YORVIPATH's year-on-year growth rate will drop sharply once the launch's 2025 quarters become the comparison base, so the better test is whether quarterly sales keep rising from ~€252M. A second test is whether YUVIWEL's enrollment-to-revenue conversion (220+ patients, 65%+ reimbursed) shows up as a clear step-up in Q3. SKYTROFA is roughly flat over the first half and is not a growth driver for now. With €812M of cash, profitable operations without the voucher and the convertible notes gone, funding is no longer the constraint it was a year ago. This was a results release; the full interim report (Form 6-K) has more detailed notes.